Rifampicin-impregnated central venous catheters: a meta-analysis of randomized controlled trials

Falagas, Matthew E.; Fragoulis, Konstantinos N.; Bliziotis, Ioannis A.; Chatzinikolaou, Ioannis

doi:10.1093/jac/dkl522

Cited by 101 publications

(53 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Two types of coating have been developed: minocycline-rifampin and chlorhexidine-silver sulfadiazine. Comparative studies concluded that the former is more efficient than the latter (200)(201)(202)(203)(204). However, the benefits of antibiotic coating for long-term intravenous catheters (LTIVC) have not yet been demonstrated.…”

Section: Currently Used Approaches Do Not Specifically Target Biofilmmentioning

confidence: 99%

Biofilm-Related Infections: Bridging the Gap between Clinical Management and Fundamental Aspects of Recalcitrance toward Antibiotics

Lebeaux

Ghigo

Beloin

2014

Microbiol Mol Biol Rev

1,009

862

View full text Add to dashboard Cite

International audienceSurface-associated microbial communities, called biofilms, are present in all environments. Although biofilms play an important positive role in a variety of ecosystems, they also have many negative effects, including biofilm-related infections in medical settings. The ability of pathogenic biofilms to survive in the presence of high concentrations of antibiotics is called "recalcitrance" and is a characteristic property of the biofilm lifestyle, leading to treatment failure and infection recurrence. This review presents our current understanding of the molecular mechanisms of biofilm recalcitrance toward antibiotics and describes how recent progress has improved our capacity to design original and efficient strategies to prevent or eradicate biofilm-related infections

show abstract

Section: Currently Used Approaches Do Not Specifically Target Biofilmmentioning

confidence: 99%

Biofilm-Related Infections: Bridging the Gap between Clinical Management and Fundamental Aspects of Recalcitrance toward Antibiotics

Lebeaux

Ghigo

Beloin

2014

Microbiol Mol Biol Rev

1,009

862

View full text Add to dashboard Cite

show abstract

“…Coatings containing combinations of antibiotics and antiseptics like minocycline and rifampin or chlorohexidin and silver-sulfadiazine have been applied to the internal and external surface of catheters. In several studies these antimicrobial coated catheters were compared to non-coated catheters, and a reduction of catheter colonization and catheter related blood-stream infections were found [66][67][68]. The antimicrobial effect of antibiotics containing coatings was more pronounced than for the antiseptic coatings.…”

Section: Antibiotic Releasing Coatingsmentioning

confidence: 99%

New Strategies in the Development of Antimicrobial Coatings: The Example of Increasing Usage of Silver and Silver Nanoparticles

2011

View full text Add to dashboard Cite

Bacterial infection from medical devices is a major problem and accounts for an increasing number of deaths as well as high medical costs. Many different strategies have been developed to decrease the incidence of medical device related infection. One way to prevent infection is by modifying the surface of the devices in such a way that no bacterial adhesion can occur. This requires modification of the complete surface with, mostly, hydrophilic polymeric surface coatings. These materials are designed to be non-fouling, meaning that protein adsorption and subsequent microbial adhesion are minimized. Incorporation of antimicrobial agents in the bulk material or as a surface coating has been considered a viable alternative for systemic application of antibiotics. However, the manifestation of more and more multi-drug resistant bacterial strains restrains the use of antibiotics in a preventive strategy. The application of silver nanoparticles on the surface of medical devices has been used to prevent bacterial adhesion and subsequent biofilm formation. The nanoparticles are either deposited directly on the device surface, or applied in a polymeric surface coating. The silver is slowly released from the surface, thereby killing the bacteria present near the surface. In the last decade there has been a surplus of studies applying the concept of silver nanoparticles as an antimicrobial agent on a range of different medical devices. The main problem however is that the exact antimicrobial mechanism of silver remains unclear. Additionally, the antimicrobial efficacy of silver on OPEN ACCESSPolymers 2011, 3 341 medical devices varies to a great extent. Here we will review existing antimicrobial coating strategies and discuss the use of silver or silver nanoparticles on surfaces that are designed to prevent medical device related infections.

show abstract

“…The minocycline-rifampin combination in impregnated central venous catheters to prevent staphylococcal biofilm infections has proven to be very successful (79,204,205). This antibiotic combination has been extensively studied, with a recent meta-analysis of randomized controlled studies showing that these impregnated catheters resulted in fewer catheter-related bloodstream infections (CR-BSI) (odds ratio [OR] ϭ 0.23) and less colonization (OR ϭ 0.46) than for nonimpregnated catheters (79,205). Rifampin resistance also did not occur using these catheters, and this may be a costeffective approach to the prevention of infections for patients who require intravenous catheters for a prolonged time (79,205).…”

Section: Staphylococcimentioning

confidence: 99%

Rifampin Combination Therapy for Nonmycobacterial Infections

2010

View full text Add to dashboard Cite

SUMMARY The increasing emergence of antimicrobial-resistant organisms, especially methicillin-resistant Staphylococcus aureus (MRSA), has resulted in the increased use of rifampin combination therapy. The data supporting rifampin combination therapy in nonmycobacterial infections are limited by a lack of significantly controlled clinical studies. Therefore, its current use is based upon in vitro or in vivo data or retrospective case series, all with major limitations. A prominent observation from this review is that rifampin combination therapy appears to have improved treatment outcomes in cases in which there is a low organism burden, such as biofilm infections, but is less effective when effective surgery to obtain source control is not performed. The clinical data support rifampin combination therapy for the treatment of prosthetic joint infections due to methicillin-sensitive S. aureus (MSSA) after extensive debridement and for the treatment of prosthetic heart valve infections due to coagulase-negative staphylococci. Importantly, rifampin-vancomycin combination therapy has not shown any benefit over vancomycin monotherapy against MRSA infections either clinically or experimentally. Rifampin combination therapy with daptomycin, fusidic acid, and linezolid needs further exploration for these severe MRSA infections. Lastly, an assessment of the risk-benefits is needed before the addition of rifampin to other antimicrobials is considered to avoid drug interactions or other drug toxicities.

show abstract

Rifampicin-impregnated central venous catheters: a meta-analysis of randomized controlled trials

Cited by 101 publications

References 46 publications

Biofilm-Related Infections: Bridging the Gap between Clinical Management and Fundamental Aspects of Recalcitrance toward Antibiotics

Biofilm-Related Infections: Bridging the Gap between Clinical Management and Fundamental Aspects of Recalcitrance toward Antibiotics

New Strategies in the Development of Antimicrobial Coatings: The Example of Increasing Usage of Silver and Silver Nanoparticles

Rifampin Combination Therapy for Nonmycobacterial Infections

Contact Info

Product

Resources

About